Terminated PHASE2 INTERVENTIONAL 2-arm NCT04634825

Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Sponsor: MacroGenics

Conditions Head and Neck Cancer Head and Neck Neoplasms Head and Neck Squamous Cell Carcinoma

Interventions Enoblituzumab Retifanlimab Tebotelimab

Updated 19 times since 2020 Last updated: Dec 18, 2023 Started: Mar 17, 2021 Primary completion: Jul 29, 2022 Completion: Jul 29, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Based on internal review of safety data

Other terminated trials from MacroGenics

See all terminations from MacroGenics

Other Head and Neck Cancer trials with similar outcome

Browse all Head and Neck Cancer trials

Listed as NCT04634825, this PHASE2 trial focuses on Head and Neck Cancer and Head and Neck Neoplasms and remains terminated or withdrawn. Sponsored by MacroGenics, it has been updated 19 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

19 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2024 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2024 [monthly]

Terminated PHASE2

▶ Show 14 earlier versions

Nov 2022 — Dec 2022 [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Jun 2022 — Nov 2022 [monthly]

Recruiting PHASE2
May 2022 — Jun 2022 [monthly]

Recruiting PHASE2
Mar 2022 — May 2022 [monthly]

Recruiting PHASE2
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE2
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE2
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE2
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE2
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE2
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE2
May 2021 — Sep 2021 [monthly]

Recruiting PHASE2
Apr 2021 — May 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Apr 2021 [monthly]

Not Yet Recruiting PHASE2
Dec 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MacroGenics

Data source: MacroGenics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Badajoz, Spain , Baltimore, United States , Barcelona, Spain , Bialystok, Poland , Budapest, Hungary , Chapel Hill, United States , Debrecen, Hungary , Dnipro, Ukraine , Dobrich, Bulgaria and 27 more locations